Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals
A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.
Kateryna Kon Research Square Nature Portfolio Positivet Cell S Specifict Cell Coronavirus Disease Covid 19
Source: news-medical.net